Ohlsson G, Schwartz M
Department of Clinical Genetics, Juliane Marie Center, University Hospital, Rigshospitalet 4062, Copenhagen, Denmark.
Hum Genet. 1997 Jan;99(1):98-102. doi: 10.1007/s004390050319.
We have developed an assay based on solid-phase minisequencing to screen for the following seven point mutations in the gene CYP21 encoding 21-hydroxylase: Pro30Leu, I2-splice, Ile172Asn, Cluster-E6, Val281Leu, Gln318Stop, and Arg356Trp. 5'-Biotinylated PCR products of CYP21 are bound to streptavidin-coated microtiter wells, where the minisequencing reaction takes place after denaturation of DNA. Depending on the sequence investigated, one specific 3H-labelled deoxyribonucleotide is incorporated to extend a detection primer. By using an appropriate set of detection primers, it is possible to screen the gene for several mutations within the same PCR amplificate. This fast and reliable method very clearly distinguishes between DNA from homozygous mutant, heterozygous, and normal individuals and is well suited for routine diagnosis of patients with 21-hydroxylase deficiency and for carrier detection.
我们开发了一种基于固相微测序的检测方法,用于筛查编码21-羟化酶的CYP21基因中的以下七个点突变:Pro30Leu、I2剪接、Ile172Asn、Cluster-E6、Val281Leu、Gln318Stop和Arg356Trp。CYP21的5'-生物素化PCR产物与链霉亲和素包被的微量滴定板结合,DNA变性后在该板上进行微测序反应。根据所研究的序列,掺入一种特定的3H标记脱氧核糖核苷酸以延伸检测引物。通过使用一组合适的检测引物,可以在同一PCR扩增产物中筛查该基因的多个突变。这种快速可靠的方法能够非常清晰地区分纯合突变体、杂合子和正常个体的DNA,非常适合用于21-羟化酶缺乏症患者的常规诊断和携带者检测。